Risk Factors for Pyogenic Liver Abscess With Carbapenem-resistant Klebsiella Pneumoniae: A Matched Case-control Study
A Matched Case-control Study of Carbapenem Resistant and Carbapenem Sensitive Klebsiella Pneumoniae Infected Pyogenic Liver Abscess
1 other identifier
observational
15
1 country
1
Brief Summary
Pyogenic liver abscess (PLA) is a complication of infectious disease, and the most common pathogen of PLA is Klebsiella pneumoniae, while PLA caused by Carbapenem-resistant Klebsiella pneumoniae (CRKP) has become a threat to public health. For achieving a better therapeutic outcome of CRKP related PLA, it is very important to figure out the basic characteristics and risk factors of CRKP-PLA. A retrospective cohort study was performed in which 15 PLA patients carriage of K pneumoniae were screened at the Xiangya hospital of central south university (changsha, China). The colonization and clinical infection isolates were analyzed by antimicrobial susceptibility testing to identify CRKP. All admission patients diagnosed with PLA who developed CRKP were included, 5 adults PLA patients with CRKP infected and 10 adults PLA patients with Carbapenem sensitive Klebsiella pneumoniae (CSKP) infected were conducted. Univariate and multivariate logistic regression was carried out using a stepwise selection method to compare prognostic factors between CRKP and CSKP groups.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Apr 2020
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 30, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
June 30, 2020
CompletedFirst Submitted
Initial submission to the registry
August 29, 2022
CompletedFirst Posted
Study publicly available on registry
August 30, 2022
CompletedAugust 30, 2022
August 1, 2022
3 months
August 29, 2022
August 29, 2022
Conditions
Outcome Measures
Primary Outcomes (1)
the survival rates
2monthes
Study Arms (2)
CRKP-PLA
Klebsiella pneumoniae were isolated from pyogenic liver abscess patients' blood or pus and the antibiotic drug sensitivity results shows it is carbapenem-resistant Klebsiella pneumoniae.
CSKP-PLA
Klebsiella pneumoniae were isolated from pyogenic liver abscess patients' blood or pus and the antibiotic drug sensitivity results shows it is carbapenem-sensitive Klebsiella pneumoniae.
Interventions
drug sensitivity results including the carbapenem-resistant Klebsiella pneumoniae and carbapenem-sensitive Klebsiella pneumoniae
Eligibility Criteria
18 years of age or older and at least one positive culture reported by the clinical microbiology laboratory for CRKP or CSKP during the hospital length of stay. Klebsiella pneumoniae were isolated and identified in the blood or pus with antibiotic drug sensitivity results.
You may qualify if:
- years of age or older. at least one positive culture reported by the clinical microbiology laboratory for CRKP or CSKP during the hospital length of stay.
- Klebsiella pneumoniae were isolated and identified in the blood or pus with antibiotic drug sensitivity results.
You may not qualify if:
- Less than 18 years old. patients with missing data without a drug sensitivity results.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Jinqing Liu
Changsha, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 29, 2022
First Posted
August 30, 2022
Study Start
April 1, 2020
Primary Completion
June 30, 2020
Study Completion
June 30, 2020
Last Updated
August 30, 2022
Record last verified: 2022-08
Data Sharing
- IPD Sharing
- Will not share